News Releases

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Zenith Epigenetics Announces Start of Several National Cancer Institute (NCI)-Sponsored Oncology Clinical Trials
July 6, 2022
Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the American Society of Clinical Oncology Conference (ASCO)
June 21, 2022
Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial
May 10, 2022
Zenith Epigenetics Announces Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIVO
February 22, 2022
Zenith Epigenetics Announces Appointment to Board of Directors and Provides Clinical Update
January 31, 2022

About

Science & Epigenetics

Programs

Newsroom

Contact

© 2022 zenithepigenetics | Legal | Privacy

Bookmark and Share